Breaking News, Financial News

Financial Report: AbbVie

Revenues up 4% in the quarter, driven by Humira

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie   2Q Revenues: $4.7 billion (+4%) 2Q Earnings: $1.1 billion (-16%) YTD Revenues: $9.0 billion (+4%) YTD Earnings: $2.0 billion (-5%) Comments: Humira sales were up 12% to $2.6 billion in the quarter. Kaletra sales were $278 million, up 1%. TriCor/Trilipix sales were down 66% to $107 million due to loss of exclusivity. Niaspan sales were up 10% to $232 million. Synthroid sales were up 24% to $153 million. Zemplar sales were up 13% to $107 million, and Creon sales were up 21% to $106 mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters